Edwards Lifesciences Q2 sales rise 13.6% to $1.74 billion; sales guidance raised
Edwards Lifesciences reported second-quarter 2026 sales of $1.74 billion, up 13.6% from a year earlier, and raised its full-year 2026 sales growth guidance to 10% to 11% on a constant currency basis. GAAP diluted EPS fell to $0.42 from $0.56 because of a $188.2 million tax valuation allowance tied to California budget legislation, while adjusted EPS rose to $0.78 from $0.67 and full-year adjusted EPS guidance of $2.95 to $3.05 was reaffirmed.
Key points
- Q2 2026 net sales were $1.74 billion, up from $1.53 billion in Q2 2025; TAVR sales were $1.26 billion, up 11.3%.
- GAAP diluted EPS was $0.42 versus $0.56 a year earlier, including a $188.2 million valuation allowance against deferred tax assets.
- Full-year 2026 sales growth guidance was raised to 10% to 11% from 9% to 11%; adjusted EPS guidance of $2.95 to $3.05 was reaffirmed.
- For Q3 2026, Edwards projects total sales of $1.63 billion to $1.71 billion and adjusted EPS of $0.71 to $0.77.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:42 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 23, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.